Aminopeptidase N (CD13) as a target for cancer chemotherapy (Q34157418)

31 July 2017

1 reference

title

Aminopeptidase N (CD13) as a target for cancer chemotherapy (English)

1 reference

31 July 2017

1 reference

1

Malin Wickström

1 reference

31 July 2017

2

Rolf Larsson

1 reference

31 July 2017

3

Peter Nygren

1 reference

31 July 2017

4

Joachim Gullbo

1 reference

31 July 2017

30 January 2011

1 reference

31 July 2017

1 reference

31 July 2017

102

1 reference

31 July 2017

3

1 reference

31 July 2017

501-508

1 reference

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

31 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

The moonlighting enzyme CD13: old and new functions to target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

The structure and main functions of aminopeptidase N.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Human aminopeptidase N is a receptor for human coronavirus 229E

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

CD13/APN is activated by angiogenic signals and is essential for capillary tube formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

CD13/APN transcription is regulated by the proto-oncogene c-Maf via an atypical response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

In vivo optical imaging of CD13/APN-expression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Role of aminopeptidase in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Clinical significance of aminopeptidase N in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Bestatin as an experimental tool in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Combination therapy with bestatin in inoperable lung cancer. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Randomized Double-Blind Placebo-Controlled Trial of Bestatin in Patients With Resected Stage I Squamous-Cell Lung Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

A doxorubicin-CNGRC-peptide conjugate with prodrug properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Generation of fusion proteins for selective occlusion of tumor vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

A new class of 5-fluoro-2'-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: synthesis, reactivity, and tumor-cell-selective cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Protease-activated “prodrugs” for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01826.X

Diagnostic evaluation of alanine aminopeptidase as serum marker for detecting cancer

21 January 2018

1 reference

12 December 2020

Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin

1 reference

12 December 2020

Prospective randomized controlled study on bestatin in resectable gastric cancer

1 reference

12 December 2020

Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion

1 reference

12 December 2020

Aminopeptidase activities in breast cancer tissue

1 reference

12 December 2020

Expression of aminopeptidase N (CD13) in mesenchymal tumors

1 reference

12 December 2020

Expression of aminopeptidase N/CD13 in human ovarian cancers

1 reference

12 December 2020

Aminopeptidases: structure and function

1 reference

12 December 2020

Aminopeptidases: towards a mechanism of action

1 reference

12 December 2020

The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis

1 reference

12 December 2020

Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells

1 reference

12 December 2020

Adjuvant bestatin (Ubenimex) treatment following full-dose local irradiation for bladder carcinoma

1 reference

12 December 2020

Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma

1 reference

12 December 2020

Alanine aminopeptidase activities in cancerous and non-cancerous human breast tissues

1 reference

12 December 2020

Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma

1 reference

12 December 2020

Gene expression in colorectal cancer

1 reference

12 December 2020

Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid

1 reference

12 December 2020

Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation

1 reference

12 December 2020

Biological significance of aminopeptidase N/CD13 in thyroid carcinomas.

1 reference

12 December 2020

Bestatin in resected lung cancer. A randomized clinical trial

1 reference

12 December 2020

Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience

1 reference

12 December 2020

Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis

1 reference

12 December 2020

Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma.

1 reference

12 December 2020

Human aminopeptidases: a review of the literature

1 reference

12 December 2020

Aminopeptidases and angiogenesis

1 reference

12 December 2020

Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer

1 reference

12 December 2020

Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.

1 reference

12 December 2020

Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy

1 reference

12 December 2020

Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion

1 reference

12 December 2020

Decreases of metallothionein and aminopeptidase N in renal cancer tissues

1 reference

12 December 2020

10.1111/J.1349-7006.2010.01826.X

Identifiers

DOI

1 reference

release_djjsmyg6nfc5nopyo6h4bvjcoe

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/djjsmyg6nfc5nopyo6h4bvjcoe

24 November 2022

mapped directly with Wikidata item

0 references

1 reference

PubMed ID

21205077